← All trials
NCT05436678
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2022
- Primary completion
- Aug 19, 2022
- Completion date
- Nov 20, 2022
- First posted
- Jun 29, 2022
- Last posted
- Oct 26, 2022
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NeuroSense Therapeutics Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.